Skip to main content

Diabetes

  • Study: One Drop|Mobile diabetes management app helps reduce A1C

    NEW YORK — One Drop on Friday announced the results of a retrospective study of people with diabetes (type 1 and type 2) using the One Drop | Mobile diabetes management app, demonstrating a 1.1% to 1.3% absolute reduction in A1C in just four months.

    The results were published Thursday in JMIR Diabetes.

  • Solera Health and higi team up to tackle diabetes

    PHOENIX — Solera Health, a provider of integrated chronic disease prevention services, today announced that it has entered into a strategic partnership with higi, the owner of the largest FDA-cleared, retail-based, self-screening network and consumer engagement platform in North America.

  • Hy-Vee ties new diabetes lifestyle management program to on-site dietitians

    WEST DES MOINES, Iowa — Hy-Vee on Friday announced it now offers a Begin for Diabetes lifestyle management program, in addition to its existing Begin and Begin 4 Kids programs. All three options are led by registered dietitians in Hy-Vee’s 244 stores across its eight-state region.

  • Blue Cross/Blue Shield launches 'Reverse It' campaign to combat prediabetes

    EAGAN, Minn. — As part of an effort to raise greater awareness around diabetes prevention, Blue Cross and Blue Shield of Minnesota is launching a campaign called "Reverse It." The campaign focuses on helping Minnesotans identify their individual risk factors for prediabetes as well as the steps they can take to lessen the likelihood of getting type 2 diabetes.

  • Health Dialog launches MTM service for health plans

    BOSTON — Rite Aid's Health Dialog on Monday introduced comprehensive Medication Therapy Management services for health plans. The new MTM services combine analytics with skilled health coaching to help patients overcome barriers to proper medication use, identify medication-related problems, promote coordination of care and improve medication management success.

  • Merck’s follow-on biologic Lusdana Nexvue gets tentative FDA approval

    SILVER SPRING, Md. — The Food and Drug Administration has given tentative approval to Merck’s follow-on biologic basal insulin Lusdana Nexvue (insulin glargine injection), the company announced Thursday. The tentative approval notes that the drug has met the required regulatory standards, but is subject to an automatic stay, as Sanofi has claimed patent infringement on its insulin product Lantus.

  • CDC's not-so-exclusive club: Diabetes now claims more than 100 million members

    ATLANTA — More than 100 million U.S. adults are now living with diabetes or prediabetes, according to a new report released Tuesday by the Centers for Disease Control and Prevention. As of 2015 30.3 million Americans, or 9.4% of the U.S. population, have diabetes. Another 84.1 million have prediabetes, a condition that if not treated often leads to type 2 diabetes within five years.

X
This ad will auto-close in 10 seconds